Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LDN-212854
Cat. No.:
OB0225LY-0209
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
LDN-212854 is a small molecule compound that is highly selective and primarily targets specific targets in certain signaling pathways.
Synonym:
LDN212854; BMP Inhibitor III; 1432597-26-6; 5-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline; 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline; 5-[6-(4-Piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
CAS No.:
1432597-26-6
Compound CID:
60182388
Formula:
C25H22N6
Formula Weight:
406.48
Specification
Relative Density:
1.33 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LDN-212854 can be used in cell signaling studies or play an important role in disease models to help understand the mechanisms of cell proliferation and apoptosis.
Library Information
Targets:
ALK family
Receptors:
ALK1; ALK2; ALK3; ALK4; ALK5
Pathways:
Stem cells; Angiogenesis; Tyrosine kinase/adaptors; TGF-β/Smad signaling
Plate Number:
AOCL-3
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
Special Max Solubility:
2eq. HCl: 20.3 mg/mL
ALogP:
2.909
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
3
